Welcome to the e-CCO Library!

P580: Early intestinal ultrasound assessment predicts endoscopic response and remission on anti-TNF treatment in Crohn’s Disease – a prospective longitudinal cohort study
Year: 2022
Source: ECCO'22
Authors: de Voogd, F.(1);Bots, S.(1);Gecse, K.(1);Gilja, O.H.(2);D'Haens, G.(1);Nylund, K.(2);
Created: Friday, 11 February 2022, 3:56 PM
P580: Improvement in disease activity is associated with less disability in a prospective study of paediatric transition patients with IBD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Picardo*1, R. Panaccione1, G. Kaplan1,2, C. Seow1,2, J. deBruyn3, Y. Leung1,4

Created: Friday, 22 February 2019, 9:41 AM
P580: Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn's disease – a multicenter “real life” study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Balint A.*1, Torocsik D.1, Palatka K.2, Szepes Z.1, Szucs M.3, Ferenci T.4, Nagy F.1, Farkas K.1, Fábián A.1, Bor R.1, Milassin A.1, Rutka M.1, Molnar T.1

Created: Wednesday, 20 February 2019, 10:36 AM
P580: Upadacitinib is effective and safe for Ulcerative Colitis: prospective real-world experience
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Friedberg, S.(1)*;Choi, D.(1);Hunold, T.(1);Choi, N.K.(1);Garcia, N.M.(1);Picker, E.A.(1);Cohen, N.A.(1);Cohen, R.D.(1);Dalal, S.R.(1);Pekow, J.(1);Sakuraba, A.(1);Krugliak Cleveland, N.(1);Rubin, D.T.(1);
Created: Friday, 14 July 2023, 11:05 AM
P580: Vitamin D substitution dose in IBD patients: Higher than recommended?
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Kojecky1*, J. Matous2, Z. Zadorova3, P. Kohout4

Created: Thursday, 21 February 2019, 9:14 AM
P581 Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn’s disease: First real-life experiences
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P.O. Schreiner1, L. Biedermann1, G. Rogler1, M. Turina2, D. Cabalzar2

Created: Thursday, 30 January 2020, 10:12 AM
P581: Complementary and alternative therapies for inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. M. Fennessy*1, C. Hanna1, N. Breslin1, D. Mc Namara1,2, S. Anwar1, A. O'Connor1,2, B. M. Ryan1,2

Created: Friday, 22 February 2019, 9:41 AM
P581: Early biological therapy within the first 12 months after diagnosis leads to higher clinical, endoscopic, and transmural remission in Crohn's disease: European multicentre study with a propensity-score matched analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Revés, J.(1)*;Fernandez-Clotet, A.(2);Ordás, I.(2);Buisson, A.(3);Ellul, P.(4);Elorza, A.(5);Aduna, M.(6);Rodríguez-Lago, I.(5);Freire, G.(7);Sousa, P.(7);Primitivo, A.(7);Delgado, I.(7);Sousa Lajas, I.(8);Raimundo, A.(8);Bettencourt, P.(8,9);Rimola, J.(10);Torres, J.(1,11);
Created: Friday, 14 July 2023, 11:05 AM
P581: Highly purified eicosapentaenoic acid, as free fatty acid, reduces fecal calprotectin levels and prevents clinical relapse in ulcerative colitis patients: a double-blind, randomized, placebo controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Scaioli E., Sartini A., Bellanova M., Campieri M., Festi D., Bazzoli F., Belluzzi A.

Created: Wednesday, 20 February 2019, 10:36 AM
P581: Patient-reported complementary and alternative medicine use in IBD: 10 years of observation among patients included in a national cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Pittet1*, N. Aslan2, N. Fournier1, A. Decollogny1, A. Schoepfer2, F. Seibold3, P.-Y. Rodondi4

Created: Thursday, 21 February 2019, 9:14 AM
P581: Pre-operative prolonged antibiotic treatment in ileocecal Crohn’s disease: single center non-randomized prospective study.
Year: 2021
Source: ECCO'21 Virtual
Authors: Vardanyan, A.(1);Ovsyannikova, V.(2);Peda , E.(3);Nanaeva, B.(3);Achkasov, S.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P581: Transmural remission improves clinical outcomes up to 5 years in patients with Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Pedro, J.(1);Botto, I.(1);Fernandes, S.(1);Lemos, J.(2);Neves, J.(3);Campelo, P.(3);Carvalho, D.(4);Bernardo, S.(1);Gonçalves, A.R.(1);Valente, A.(1);Moura Santos, P.(1);Rosa, I.(2);Tavares de Sousa, H.(3);Ramos, J.(4);Venâncio, J.(5);Leitão, J.(6);Claro, I.(2);Correia, L.(1);Tato Marinho, R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P582 Adalimumab therapeutic drug monitoring: Does time of testing matter?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Shields1, J.P. Seenan1, A. Dunlop2, P. Galloway2, J. Macdonald1

Created: Thursday, 30 January 2020, 10:12 AM
P582: Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Yanofsky, R.(1);Abduallah, Y.(1);Golovics, P.(2);Lakatos, P.L.(2);Bitton, A.(2);Wild, G.(2);Afif, W.(2);Bessissow, T.(2);
Created: Friday, 11 February 2022, 3:56 PM
P582: Effectiveness and nephrotoxicity of long-term tacrolimus administration in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Haga*1, T. Shibuya1, K. Okahara1, M. Kamei1, M. Takahashi1, O. Nomura1, D. Ishikawa1, N. Sakamoto1, T. Osada2, A. Nagahara1

Created: Friday, 22 February 2019, 9:41 AM
P582: Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vermeire, S.(1)*;Sands, B.E.(2);Dubinsky, M.C.(3);Feagan, B.G.(4);Panaccione, R.(5);Jairath, V.(6);Yarur, A.(7);Chiorean, M.(8);Panés, J.(9);Goetsch, M.(10);Rabbat, C.J.(11);Shah, P.(12);Wu, J.(13);Ghosh, S.(14);
Created: Friday, 14 July 2023, 11:05 AM
P582: Insights on the sphingolipid profile in patients with short bowel syndrome and consecutive intestinal failure
Year: 2021
Source: ECCO'21 Virtual
Authors: Kubesch, A.(1);Knauer, F.(1);Thomas, D.(2);Jakobi, K.(3);Filmann, N.(4);Zeuzem, S.(1);Pfeilschifter, J.(3);Grammatikos, G.(1);Blumenstein, I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P582: The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Han S., Kim S., Kim J., Kwon D.-H., Choi J.-S., Yoon S.-R., Yun S.-H., Kim D.-S., Bae J.-H., Choi H.-J., Sung H.-Y., Yoon S.-W.

Created: Wednesday, 20 February 2019, 10:36 AM
P582: Vedolizumab: Effects on liver function in an IBD and IBD/PSC cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Doherty*, M. Buckley, G. Cullen, G. Horgan, H. Mulcahy, G. Doherty, J. Sheridan

Created: Thursday, 21 February 2019, 9:14 AM
P583 The prevalence of side effects to immunomodulators and biologics in patients with Crohn’s disease intestinal failure compared with Crohn’s disease without intestinal failure
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Bouri1, J. Geldof1, J. Willsmore2, S. Donnelly2, S. Gabe2, A. Hart1

Created: Thursday, 30 January 2020, 10:12 AM